This Article Full Text Full Text (PDF) All Versions of this Article: 108/3/348    most recent 01.CIR.0000080325.94345.8Bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maack, C. Articles by Engelhardt, S. Search for Related Content PubMed PubMed Citation Articles by Maack, C. Articles by Engelhardt, S. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Hazardous Substances DB METOPROLOL PROPRANOLOL HYDROCHLORIDE Related Collections Congestive Cardiovascular Pharmacology Genetically altered mice Autonomic, reflex, and neurohumoral control of circulation Receptor pharmacology

(Circulation. 2003;108:348.)
© 2003 American Heart Association, Inc.

Basic Science Reports

Partial Agonist Activity of Bucindolol Is Dependent on the Activation State of the Human ß₁-Adrenergic Receptor

Christoph Maack, MD; Michael Böhm, MD; Lydia Vlaskin, MS; Ewtim Dabew, MS; Kristina Lorenz; Hans-Joachim Schäfers, MD, PhD; Martin J. Lohse, MD; Stefan Engelhardt, MD, PhD

From the Klinik und Poliklinik für Innere Medizin III (C.M., M.B., E.D.) and the Klinik für Herz- und Thoraxchirurgie (H.-J.S.), Universität des Saarlandes, Homburg/Saar; and the Institut für Pharmakologie und Toxikologie (L.V., C.L., M.J.L., S.E.), Universität Würzburg, Würzburg, Germany.

Correspondence to Stefan Engelhardt, Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Straße 9, 97078 Würzburg, Germany. E-mail engelhardt{at}toxi.uni-wuerzburg.de

Background— In contrast to other ß-blockers, bucindolol has failed to reduce mortality in patients with chronic heart failure. It is currently debated whether this is due to partial agonist activity of this agent. We investigated whether conflicting results previously reported concerning the intrinsic activity of bucindolol can be explained by species differences or by different activation states of ß-adrenergic receptors (ß-ARs) in the respective tissues.

Methods and Results— On isolated right atria from transgenic mice with cardiac overexpression of human ß₁-ARs, bucindolol led to a greater increase in beating frequency (P<0.05) compared with wild-type mice. The increase amounted to 47% of the effect of xamoterol and was blocked by propranolol. On isolated, electrically stimulated, left ventricular muscle-strip preparations from failing human myocardium, bucindolol did not change the force of contraction under control conditions. In myocardial preparations pretreated with metoprolol (30 µmol/L, 90 minutes, subsequent washout), bucindolol significantly increased the force of contraction (P<0.001 vs control). In nonfailing atrial myocardium, isoproterenol pretreatment (1 µmol/L, 60 minutes) abolished the positive inotropic effect of xamoterol that was present under control conditions (P<0.05 vs control). The inotropic effects of bucindolol or xamoterol were inversely correlated to the inotropic response to forskolin in the respective specimens (r=-0.75 and -0.74, respectively; P<0.005).

Conclusions— We conclude that bucindolol is a partial agonist at the human ß₁-AR. In human failing myocardium, its partial agonist activity is masked by increased activation states of ß-ARs and is unmasked after in vitro pretreatment with metoprolol. Thus, the partial agonist activity of bucindolol is dependent on the activation state of the human ß₁-AR.

Key Words: receptors, adrenergic, beta • inotropic agents • heart failure • genetics

This article has been cited by other articles:

				E. H. Aburawi, A. Berg, P. Liuba, and E. Pesonen Effects of cardiopulmonary bypass surgery on coronary flow in children assessed with transthoracic Doppler echocardiography Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1138 - H1143. [Abstract] [Full Text] [PDF]

				S. B. Liggett, J. Mialet-Perez, S. Thaneemit-Chen, S. A. Weber, S. M. Greene, D. Hodne, B. Nelson, J. Morrison, M. J. Domanski, L. E. Wagoner, et al. A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure PNAS, July 25, 2006; 103(30): 11288 - 11293. [Abstract] [Full Text] [PDF]

				M. Floreani, G. Froldi, L. Quintieri, K. Varani, P. A. Borea, M. T. Dorigo, and P. Dorigo In Vitro Evidence That Carteolol Is a Nonconventional Partial Agonist of Guinea Pig Cardiac {beta}1-Adrenoceptors: A Comparison with Xamoterol J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1386 - 1395. [Abstract] [Full Text] [PDF]

				M. J. Lohse, S. Engelhardt, and T. Eschenhagen What Is the Role of {beta}-Adrenergic Signaling in Heart Failure? Circ. Res., November 14, 2003; 93(10): 896 - 906. [Abstract] [Full Text] [PDF]